GLUCOPHAGE XR

LOE Approaching

metformin hydrochloride

NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT06823856Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Started May 2025
64 enrolled
Diabetes Mellitus Type 2
NCT06792968Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Started Mar 2025
64 enrolled
Diabetes Mellitus Type 2
NCT06766500Phase 1Completed

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Started Jan 2025
64 enrolled
Diabetes Mellitus Type 2
NCT04288778Phase 4Completed

A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes

Started Nov 2020
276 enrolled
Diabetes Mellitus
NCT03048500Phase 2Unknown

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Started Jul 2017
17 enrolled
Recurrent Non-Small Cell Lung CarcinomaStage III Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung Cancer+2 more
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers